{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:59:15Z","timestamp":1790787555218,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["111-2634-F-007-023"],"award-info":[{"award-number":["111-2634-F-007-023"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["MOE 111QR001I5"],"award-info":[{"award-number":["MOE 111QR001I5"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["108-2221-E-007-104-MY5"],"award-info":[{"award-number":["108-2221-E-007-104-MY5"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111-2628-E-007-015"],"award-info":[{"award-number":["111-2628-E-007-015"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX112-11015BI"],"award-info":[{"award-number":["NHRI-EX112-11015BI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jconrel.2023.02.016","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T18:58:58Z","timestamp":1677610738000},"page":"14-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Nanotechnology for next-generation cancer immunotherapy: State of the art and future perspectives"],"prefix":"10.1016","volume":"356","author":[{"given":"Yunching","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.02.016_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113927","article-title":"Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors","volume":"177","author":"Ye","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0020","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41551-018-0266-2","article-title":"Challenges towards the realization of individualized cancer vaccines","volume":"2","author":"Tureci","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0030","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0040","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jconrel.2022.01.004","article-title":"Surface glycan targeting for cancer nano-immunotherapy","volume":"342","author":"Choi","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0045","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jconrel.2021.11.043","article-title":"Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment","volume":"341","author":"Hope","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0050","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2022.02.023","article-title":"Leveraging biomaterials for enhancing T cell immunotherapy","volume":"344","author":"Liao","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0060","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1038\/s41467-022-31926-9","article-title":"Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment","volume":"13","author":"Reda","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201905751","article-title":"Dual-locking nanoparticles disrupt the PD-1\/PD-L1 pathway for efficient cancer immunotherapy","volume":"31","author":"Zhang","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0070","article-title":"An antigen-delivery protein nanoparticle combined with anti-PD-1 checkpoint inhibitor has curative efficacy in an aggressive melanoma model","volume":"3","author":"Neek","year":"2020","journal-title":"Adv. Ther. (Weinh.)"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0075","doi-asserted-by":"crossref","first-page":"8318","DOI":"10.1021\/acs.nanolett.9b03968","article-title":"Aggregable nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment","volume":"19","author":"Ruan","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0080","doi-asserted-by":"crossref","first-page":"18885","DOI":"10.1039\/D0NR04213G","article-title":"Microneedles loaded with anti-PD-1-cisplatin nanoparticles for synergistic cancer immuno-chemotherapy","volume":"12","author":"Lan","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0085","article-title":"A dual immunotherapy nanoparticle improves T-cell activation and cancer immunotherapy","volume":"30","author":"Mi","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0090","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1038\/s41467-021-27434-x","article-title":"Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0095","doi-asserted-by":"crossref","first-page":"eaax5032","DOI":"10.1126\/sciadv.aax5032","article-title":"Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer","volume":"6","author":"Huang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2022.01.049","article-title":"Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells","volume":"343","author":"Han","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0105","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1021\/acs.nanolett.7b02636","article-title":"Integrin-assisted T-cell activation on nanostructured hydrogels","volume":"17","author":"Guasch","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0110","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nbt.4181","article-title":"Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery","volume":"36","author":"Tang","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0115","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2021.11.028","article-title":"Nanomaterials targeting tumor associated macrophages for cancer immunotherapy","volume":"341","author":"Zhao","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0120","doi-asserted-by":"crossref","first-page":"eaaz6579","DOI":"10.1126\/sciadv.aaz6579","article-title":"Cellular backpacks for macrophage immunotherapy","volume":"6","author":"Shields","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202103258","article-title":"Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy","volume":"33","author":"Kang","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2022.01.021","article-title":"Immunostimulation of tumor microenvironment by targeting tumor-associated macrophages with hypoxia-responsive nanocomplex for enhanced anti-tumor therapy","volume":"343","author":"Kang","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0135","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41467-021-21497-6","article-title":"Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy","volume":"12","author":"Jiang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0140","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1039\/D0SC01146K","article-title":"Biofunctional Janus particles promote phagocytosis of tumor cells by macrophages","volume":"11","author":"Zhang","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202004240","article-title":"Nanoparticle-enabled dual modulation of phagocytic signals to improve macrophage-mediated cancer immunotherapy","volume":"16","author":"Zhang","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0150","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2018.05.018","article-title":"Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy","volume":"281","author":"Ou","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0155","doi-asserted-by":"crossref","first-page":"23714","DOI":"10.1073\/pnas.1906346116","article-title":"Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0160","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1021\/jacs.9b04621","article-title":"Deep tumor penetration of drug-loaded nanoparticles by click reaction-assisted immune cell targeting strategy","volume":"141","author":"Lee","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0165","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006486","article-title":"Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease","volume":"2","author":"Goel","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0170","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/s41565-019-0570-3","article-title":"Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies","volume":"14","author":"Sung","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0175","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jconrel.2022.10.047","article-title":"CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma","volume":"352","author":"Hsieh","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0180","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jconrel.2021.10.016","article-title":"Reinforcing vascular normalization therapy with a bi-directional nano-system to achieve therapeutic-friendly tumor microenvironment","volume":"340","author":"Deng","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0185","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2022.03.008","article-title":"Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy","volume":"345","author":"Mpekris","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0190","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neo.2015.08.004","article-title":"Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models","volume":"17","author":"Rios-Doria","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/fon-2017-0338","article-title":"HALO-109-301: a phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer","volume":"14","author":"Doherty","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0200","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121516","article-title":"Remotely boosting hyaluronidase activity to normalize the hypoxic immunosuppressive tumor microenvironment for photothermal immunotherapy","volume":"284","author":"Liu","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0210","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1021\/acs.nanolett.6b00820","article-title":"Hyaluronidase embedded in nanocarrier PEG shell for enhanced tumor penetration and highly efficient antitumor efficacy","volume":"16","author":"Zhou","year":"2016","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0215","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1021\/acsnano.9b02395","article-title":"Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors","volume":"13","author":"Zinger","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0220","article-title":"FAP-targeted photodynamic therapy mediated by ferritin nanoparticles elicits an immune response against cancer cells and cancer associated fibroblasts","volume":"31","author":"Zhou","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0225","doi-asserted-by":"crossref","first-page":"10674","DOI":"10.1073\/pnas.1819889116","article-title":"Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy","volume":"116","author":"Chauhan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0230","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/gutjnl-2021-325180","article-title":"Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours","volume":"71","author":"Huang","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0235","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jconrel.2021.10.015","article-title":"Tumor-dilated polymersome nanofactories for enhanced enzyme prodrug chemo-immunotherapy","volume":"339","author":"Japir","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0240","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2021.10.026","article-title":"Adaptable peptide-based therapeutics modulating tumor microenvironment for combinatorial radio-immunotherapy","volume":"340","author":"Li","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0245","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1039\/D2TB00197G","article-title":"Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer","volume":"10","author":"Zang","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0250","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.hoc.2018.12.001","article-title":"Cancer vaccines","volume":"33","author":"DeMaria","year":"2019","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2022.05.004","article-title":"Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance","volume":"347","author":"Muraoka","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0260","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jconrel.2022.03.054","article-title":"Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy","volume":"345","author":"Doshi","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0265","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.biomaterials.2016.05.008","article-title":"Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy","volume":"98","author":"Qian","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0270","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41578-019-0110-7","article-title":"Material design for lymph node drug delivery","volume":"4","author":"Schudel","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0275","article-title":"Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin\/CD169","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0280","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jconrel.2022.02.027","article-title":"Aluminum nanoparticles deliver a dual-epitope peptide for enhanced anti-tumor immunotherapy","volume":"344","author":"Bai","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0285","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.7150\/thno.22056","article-title":"The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide","volume":"8","author":"Lai","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0290","first-page":"2002577","article-title":"Modularly programmable nanoparticle vaccine based on polyethyleneimine for personalized cancer immunotherapy","volume":"8","author":"Nam","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2019.03.037","article-title":"Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy","volume":"207","author":"Xu","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0300","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41563-020-0793-6","article-title":"A DNA nanodevice-based vaccine for cancer immunotherapy","volume":"20","author":"Liu","year":"2021","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0305","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nbt.4313","article-title":"Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification","volume":"37","author":"Bulik-Sullivan","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202100356","article-title":"Polymer nanoparticle-mediated delivery of oxidized tumor lysate-based cancer vaccines","volume":"22","author":"Berti","year":"2022","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0315","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1021\/acsnano.7b09041","article-title":"Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination","volume":"12","author":"Yang","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0320","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1021\/acs.nanolett.2c00500","article-title":"Surgical tumor-derived photothermal nanovaccine for personalized cancer therapy and prevention","volume":"22","author":"Li","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0325","doi-asserted-by":"crossref","first-page":"1777624","DOI":"10.1080\/2162402X.2020.1777624","article-title":"Trial watch: STING agonists in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0330","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0335","first-page":"e2201895","article-title":"Responsive multivesicular polymeric nanovaccines that codeliver STING agonists and neoantigens for combination tumor immunotherapy","author":"Su","year":"2022","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0340","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41578-021-00372-2","article-title":"Designing spatial and temporal control of vaccine responses","volume":"7","author":"Roth","year":"2022","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0345","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2021.09.033","article-title":"Considerations for the delivery of STING ligands in cancer immunotherapy","volume":"339","author":"Petrovic","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0350","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz6606","article-title":"Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy","volume":"12","author":"Lu","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0355","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41551-020-00675-9","article-title":"Prolonged activation of innate immune pathways by a polyvalent STING agonist","volume":"5","author":"Li","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0360","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0365","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0370","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jconrel.2022.03.045","article-title":"Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy","volume":"345","author":"Meng","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0375","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jconrel.2022.01.047","article-title":"Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy","volume":"343","author":"Yoo","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0380","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","author":"Liu","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0385","article-title":"Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0390","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jconrel.2022.01.003","article-title":"Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy","volume":"342","author":"Ni","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0395","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jconrel.2022.01.024","article-title":"Intratumoral delivery of brachytherapy and immunotherapy by a thermally triggered polypeptide depot","volume":"343","author":"Kelly","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0400","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2022.05.003","article-title":"Immunogenicity-boosted cancer immunotherapy based on nanoscale metal-organic frameworks","volume":"347","author":"Li","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0405","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jconrel.2022.03.026","article-title":"Combined nano cancer immunotherapy based on immune status in a tumor microenvironment","volume":"345","author":"Nakamura","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0410","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2022.04.048","article-title":"ApoE-mediated systemic nanodelivery of granzyme B and CpG for enhanced glioma immunotherapy","volume":"347","author":"Wei","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0415","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.02.016_bb0420","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0425","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1007\/s00262-021-02892-w","article-title":"Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients","volume":"70","author":"Ishikawa","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2023.02.016_bb0430","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923001268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923001268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:36:18Z","timestamp":1759163778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923001268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":86,"alternative-id":["S0168365923001268"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.02.016","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanotechnology for next-generation cancer immunotherapy: State of the art and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}